|Bid||7.58 x 1100|
|Ask||7.97 x 800|
|Day's Range||7.52 - 7.91|
|52 Week Range||7.22 - 48.64|
|Beta (5Y Monthly)||0.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.00|
Patient deaths, testing concerns and “weak arguments.” Those are just a few of the issues the FDA had with Sarepta Therapeutics’s recent drug application, according to new documents released this week.
Wave Life Sciences took its first steps this week after a major corporate setback, releasing early data on one of the two potential treatments for Huntington’s disease, which it's developing with Takeda Pharmaceutical Co. Ltd. The drugs are now Wave’s most advanced products in development following its decision earlier this month to halt testing on its Duchenne muscular dystrophy treatment. In an interview with the Business Journal following the news, Wave's CEO stood by the decision to start small.
Wave Life Sciences stock collapsed Monday after the biotech company's experimental Huntington's disease treatment underperformed a rival drug from Roche and Ionis Pharmaceuticals.
Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced topline data from the ongoing Phase 1b/2a PRECISION-HD2 trial evaluating investigational therapy WVE-120102, designed to be the first allele-selective approach to treat Huntington’s disease (HD). In an analysis comparing all patients treated with multiple intrathecal doses of WVE-120102 to placebo, a statistically significant reduction of 12.4% (p
The drug was safe and well-tolerated but showed no difference in total huntingtin protein compared with placebo.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Wave Life Sciences stock crashed Monday after the biotech company scrapped development of two Duchenne muscular dystrophy treatments. The decision will benefit rival Sarepta Therapeutics.
Shortly after a competitor announced a victory against the rare disease Duchenne muscular dystrophy, Cambridge biotech Wave Life Sciences announced a defeat.
Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced its decision to discontinue development of suvodirsen for patients with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 51 skipping, based on its interim analysis of the Phase 1 open-label extension (OLE) study. As a result of this decision, the company is immediately discontinuing the two suvodirsen trials, the OLE study and the Phase 2/3 DYSTANCE 51 trial.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Over the last month the Wave Life Sciences Ltd. (NASDAQ:WVE) has been much stronger than before, rebounding by 42...
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.47% and -53.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Fast Track designation for suvodirsen received from the U.S. FDA Interim analysis of dystrophin expression from suvodirsen open-label extension study expected in 4Q 2019.
Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 20% in 2019 (through September 30th). Conversely, hedge […]
CAMBRIDGE, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to suvodirsen for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 51 skipping. The designation was based on comprehensive in vitro and in vivo nonclinical data that support the potential for suvodirsen to address a significant unmet medical need.
CAMBRIDGE, Mass., Sept. 06, 2019 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for.
CAMBRIDGE, Mass., Aug. 26, 2019 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people.